Logo image of VCNX

VACCINEX INC (VCNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VCNX - US9186403013 - Common Stock

1.41 USD
-2.24 (-61.37%)
Last: 12/17/2024, 9:35:36 PM
1.3211 USD
-0.09 (-6.3%)
After Hours: 12/17/2024, 9:35:36 PM
Fundamental Rating

0

VCNX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. Both the profitability and financial health of VCNX have multiple concerns. VCNX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year VCNX has reported negative net income.
  • In the past year VCNX has reported a negative cash flow from operations.
  • In the past 5 years VCNX always reported negative net income.
  • In the past 5 years VCNX always reported negative operating cash flow.
VCNX Yearly Net Income VS EBIT VS OCF VS FCFVCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of VCNX (-382.72%) is worse than 96.62% of its industry peers.
Industry RankSector Rank
ROA -382.72%
ROE N/A
ROIC N/A
ROA(3y)-344.5%
ROA(5y)-394.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VCNX Yearly ROA, ROE, ROICVCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

  • VCNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VCNX Yearly Profit, Operating, Gross MarginsVCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

  • VCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VCNX has been increased compared to 1 year ago.
  • VCNX has a worse debt/assets ratio than last year.
VCNX Yearly Shares OutstandingVCNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
VCNX Yearly Total Debt VS Total AssetsVCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

  • VCNX has an Altman-Z score of -116.17. This is a bad value and indicates that VCNX is not financially healthy and even has some risk of bankruptcy.
  • VCNX's Altman-Z score of -116.17 is on the low side compared to the rest of the industry. VCNX is outperformed by 98.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -116.17
ROIC/WACCN/A
WACC10.93%
VCNX Yearly LT Debt VS Equity VS FCFVCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

2.3 Liquidity

  • VCNX has a Current Ratio of 0.77. This is a bad value and indicates that VCNX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.77, VCNX is doing worse than 90.39% of the companies in the same industry.
  • A Quick Ratio of 0.77 indicates that VCNX may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.77, VCNX is not doing good in the industry: 90.39% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
VCNX Yearly Current Assets VS Current LiabilitesVCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

  • VCNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.54%, which is quite impressive.
  • The Revenue for VCNX has decreased by -51.19% in the past year. This is quite bad
  • Measured over the past years, VCNX shows a decrease in Revenue. The Revenue has been decreasing by -4.67% on average per year.
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
Revenue 1Y (TTM)-51.19%
Revenue growth 3Y-3.02%
Revenue growth 5Y-4.67%
Sales Q2Q%160%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VCNX Yearly Revenue VS EstimatesVCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
VCNX Yearly EPS VS EstimatesVCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 -200 -400 -600 -800

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • VCNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VCNX Price Earnings VS Forward Price EarningsVCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VCNX Per share dataVCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • VCNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VACCINEX INC

NASDAQ:VCNX (12/17/2024, 9:35:36 PM)

After market: 1.3211 -0.09 (-6.3%)

1.41

-2.24 (-61.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)N/A
Inst Owners51.85%
Inst Owner Change0%
Ins Owners0.38%
Ins Owner Change0%
Market Cap3.78M
Revenue(TTM)388.00K
Net Income(TTM)-18.58M
Analysts85.71
Price TargetN/A
Short Float %0.17%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.92
FCFYN/A
OCF(TTM)-5.91
OCFYN/A
SpS0.14
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -382.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-344.5%
ROA(5y)-394.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.15%
Cap/Sales 5.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z -116.17
F-Score4
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)41.02%
Cap/Depr(5y)49.77%
Cap/Sales(3y)17.1%
Cap/Sales(5y)22.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-51.19%
Revenue growth 3Y-3.02%
Revenue growth 5Y-4.67%
Sales Q2Q%160%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.23%
OCF growth 3YN/A
OCF growth 5YN/A

VACCINEX INC / VCNX FAQ

What is the ChartMill fundamental rating of VACCINEX INC (VCNX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to VCNX.


Can you provide the valuation status for VACCINEX INC?

ChartMill assigns a valuation rating of 0 / 10 to VACCINEX INC (VCNX). This can be considered as Overvalued.


How profitable is VACCINEX INC (VCNX) stock?

VACCINEX INC (VCNX) has a profitability rating of 0 / 10.


What is the financial health of VACCINEX INC (VCNX) stock?

The financial health rating of VACCINEX INC (VCNX) is 0 / 10.